OBJECTIVE: The presence of anxiety disorders (AD) in schizophrenia (SZ) is attracting increasing interest. However, published studies have yielded very broad variations in prevalence rates across studies. The current meta-analysis sought to (1) investigate the prevalence of co-occurring AD in SZ by reporting pooled prevalence rates and (2) identify potential sources of variations in reported rates that could guide our efforts to identify and treat these co-occurring disorders in patients with SZ. METHODS: We performed a systematic search of studies reporting prevalence of AD in SZ and related psychotic disorders. Mean prevalence rates and 95% confidence intervals (CIs) were first computed for each disorder. We then examined the impact of potential moderators related to patient sampling or to AD assessment methods on these rates. RESULTS: Fifty-two eligible studies were identified. Pooled prevalence rates and CIs were 12.1% (7.0%-17.1%) for obsessive-compulsive disorders, 14.9% (8.1%-21.8%) for social phobia, 10.9% (2.9%-18.8%) for generalized AD, 9.8% (4.3%-15.4%) for panic disorders, and 12.4% (4.0%-20.8%) for post-traumatic stress disorders. For all disorders, we found significant heterogeneity in rates across studies. This heterogeneity could at least partially be explained by the effect of moderator variables related to patient characteristics or assessment methods. CONCLUSIONS: AD are highly prevalent in SZ, but important variations in rates are observed between studies. This meta-analysis highlights several factors that affect risk for, or detection of AD in SZ, and could, thus, have an important impact on treatment and outcome of SZ patients.
OBJECTIVE: The presence of anxiety disorders (AD) in schizophrenia (SZ) is attracting increasing interest. However, published studies have yielded very broad variations in prevalence rates across studies. The current meta-analysis sought to (1) investigate the prevalence of co-occurring AD in SZ by reporting pooled prevalence rates and (2) identify potential sources of variations in reported rates that could guide our efforts to identify and treat these co-occurring disorders in patients with SZ. METHODS: We performed a systematic search of studies reporting prevalence of AD in SZ and related psychotic disorders. Mean prevalence rates and 95% confidence intervals (CIs) were first computed for each disorder. We then examined the impact of potential moderators related to patient sampling or to AD assessment methods on these rates. RESULTS: Fifty-two eligible studies were identified. Pooled prevalence rates and CIs were 12.1% (7.0%-17.1%) for obsessive-compulsive disorders, 14.9% (8.1%-21.8%) for social phobia, 10.9% (2.9%-18.8%) for generalized AD, 9.8% (4.3%-15.4%) for panic disorders, and 12.4% (4.0%-20.8%) for post-traumatic stress disorders. For all disorders, we found significant heterogeneity in rates across studies. This heterogeneity could at least partially be explained by the effect of moderator variables related to patient characteristics or assessment methods. CONCLUSIONS: AD are highly prevalent in SZ, but important variations in rates are observed between studies. This meta-analysis highlights several factors that affect risk for, or detection of AD in SZ, and could, thus, have an important impact on treatment and outcome of SZ patients.
Authors: Renee D Goodwin; Xavier F Amador; Dolores Malaspina; Scott A Yale; Raymond R Goetz; Jack M Gorman Journal: Schizophr Res Date: 2003-05-01 Impact factor: 4.939
Authors: Holly J Carlisle; Tinh N Luong; Andrew Medina-Marino; Leslie Schenker; Eugenia Khorosheva; Tim Indersmitten; Keith M Gunapala; Andrew D Steele; Thomas J O'Dell; Paul H Patterson; Mary B Kennedy Journal: J Neurosci Date: 2011-11-09 Impact factor: 6.167
Authors: Lauren C Ng; Liana J Petruzzi; M Claire Greene; Kim T Mueser; Christina P C Borba; David C Henderson Journal: J Nerv Ment Dis Date: 2016-08 Impact factor: 2.254
Authors: Stephanie N L Schmidt; Sabrina C Fenske; Peter Kirsch; Daniela Mier Journal: Eur Arch Psychiatry Clin Neurosci Date: 2018-10-25 Impact factor: 5.270
Authors: Laura A Bajor; Douglas Gunzler; Douglas Einstadter; Charles Thomas; Richard McCormick; Adam T Perzynski; Stephanie W Kanuch; Kristin A Cassidy; Neal V Dawson; Martha Sajatovic Journal: Int J Psychiatry Med Date: 2015-06-09 Impact factor: 1.210
Authors: Daniel Fulford; Tara A Niendam; Erin G Floyd; Cameron S Carter; Daniel H Mathalon; Sophia Vinogradov; Barbara K Stuart; Rachel L Loewy Journal: Schizophr Res Date: 2013-04-12 Impact factor: 4.939
Authors: Joanne Voisey; Christopher D Swagell; Ian P Hughes; Jason P Connor; Bruce R Lawford; Ross M Young; C Phillip Morris Journal: Behav Brain Funct Date: 2010-07-09 Impact factor: 3.759